A Phase I Study of Nilotinib plus Radiation in High-Risk Chordoma

In this phase I study we treated 23 high-risk chordoma patients with nilotinib plus radiation therapy. We determined the maximum tolerated dose was 200 mg per day when combined with radiation. The median progression free survival was 58.15 months (95% CI: 39.10-inf) and 2-year overall survival rate was 95%. Nilotinib plus radiotherapy is safe in this population. Further study will be required to determine if this is superior than radiation with or without surgery alone.

https://ift.tt/2Mea6dD